Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

MaaT Pharma (MAAT) Stock Price & Analysis

MAAT Stock Chart & Stats

€1.03€0.01(0.79%)
At close: 5:12 PM GMT+1
€1€2€33 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 1.02 - EUR 1.12
52-Week Range
EUR 0.90 - EUR 8.62
Previous Close
EUR 1.07
Volume
N/A
Average Volume (3M)
110.11K
Market Cap
EUR 19.20M
Enterprise Value
EUR 51.54M
Total Cash (Recent Filing)
EUR 17.10M
Total Debt (Recent Filing)
EUR 23.78M
Price to Earnings (P/E)
―
Beta
0.07
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Traction

The progression from no recorded revenue in 2020 to approximately €4.5M in 2025 indicates emerging commercial traction. Continued top-line expansion could provide a foundation for operating leverage if MaaT Pharma can scale products and improve profitability over the coming quarters.

Improving Operating Cash Outflow

Although cash generation remains negative, the reduction in operating cash outflow shows some improvement in cash-use intensity versus the prior year. If sustained alongside revenue growth, this could extend financial flexibility and reduce the pace at which the company consumes funding.

Specialized Microbiome Platform

MaaT Pharma has a clearly defined therapeutic specialization rather than a broadly dispersed development strategy. Its standardized, full-spectrum microbiome approach targets serious oncology and hematology complications, creating a focused platform for advancing products in a specific medical need.

Bears Say

Widening Net Losses

Losses are increasing despite the company reaching approximately €4.5M of revenue, showing that the current cost base is not yet scaling with commercial activity. Persistent and widening deficits can delay break-even, require continued financing, and constrain investment flexibility over the medium term.

Weakening Balance Sheet

Higher debt combined with sharply compressed equity has materially reduced the capital cushion supporting the business. This weaker balance-sheet structure increases financial risk, limits resilience if operating losses persist, and may make future funding needs more consequential for shareholders.

Persistent Cash Burn

Negative free cash flow means the business is not currently funding operations and investment internally. Continued cash consumption, even after some operating improvement, leaves MaaT Pharma reliant on external capital while it develops products and works toward sustainable profitability.

MaaT Pharma News

MAAT FAQ

What was MaaT Pharma’s price range in the past 12 months?
MaaT Pharma lowest stock price was €0.90 and its highest was €8.62 in the past 12 months.
What is MaaT Pharma’s market cap?
MaaT Pharma’s market cap is €19.20M.
When is MaaT Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MaaT Pharma’s earnings last quarter?
MaaT Pharma released its earnings results on Sep 29, 2026. The company reported -€0.972 earnings per share for the quarter.
Is MaaT Pharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does MaaT Pharma pay dividends?
MaaT Pharma does not currently pay dividends.
What is MaaT Pharma’s EPS estimate?
MaaT Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MaaT Pharma have?
MaaT Pharma has 18,856,394 shares outstanding.
What happened to MaaT Pharma’s price movement after its last earnings report?
MaaT Pharma reported an EPS of -€0.972 in its last earnings report. Following the earnings report the stock price went down -0.877%.
Which hedge fund is a major shareholder of MaaT Pharma?
Currently, no hedge funds are holding shares in FR:MAAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology